CAV1 and breast cancer: Importantly, combination of the autophagy inhibitor HCQ with Doxo dramatically diminishes the superiority of the CAV1 KD tumors (Figures 7C–7F), suggesting a possible stratagem to overcome Doxo resistance in CAV1-downregulated breast cancer patients by targeting autophagy.